Boston Scientific: Bladder cancer visualization and resection
There is a clinical need to improve visualization and resection of non-muscle invasive bladder cancer beyond existing techniques. Bladder cancer is the sixth most common cancer in the United States. Urethelial (transition cell) carcinoma is the most common form of bladder cancer. Bladder cancer is 4 times more common in men versus women and has a significant economic burden due to high rates of recurrence and need for surveillance. Early detection prior to muscle invasion is key to improving outcomes so diagnosis at non-muscle-invasive bladder cancer (NMIBC) stage significantly reduces risk of progression and increases survival. Current practice includes transurethral resection of bladder tumor (TURBT), cystoscopy for visualization, and intravesical therapy (IVT).